At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 155 enrolled
Drug / intervention
FOY-305 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)
In Brief
A Phase 3 clinical trial evaluating FOY-305 and Placebo for SARS-CoV-2 Infection (COVID-19). Completed, enrolled 155 participants across 25 sites.
Detailed Summary
To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection (COVID-19)
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedDec 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedDec 8, 2020
Enrollment StartNov 9, 2020
Primary CompletionMar 26, 2021
Study CompletionApr 9, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.6 years ago
Interventions
FOY-305drug
Specified Dosage and Duration of Treatment
Placebodrug
Specified Dosage and Duration of Treatment